Gene Therapy Analytical Development Summit on October 21-23, 2025 in Boston, United States

As gene therapies evolve beyond AAV to include mRNA, CRISPR-based platforms, and novel capsids, analytical strategies must advance in parallel to meet rising complexity and regulatory expectations. With increased pressure for analytical rigor, potency relevance, and product consistency, the need for robust, forward-thinking solutions is more urgent than ever.

The 7th Gene Therapy Analytical Development Summit returns to Boston this October as the industry’s most comprehensive event dedicated to analytical excellence across the gene therapy development lifecycle-from early research through to BLA submission and commercial readiness.

This year’s summit will deliver practical, data-driven insights on validating potency assays and genome integrity analytics across diverse delivery platforms to ensure consistency, safety, and regulatory compliance. Attendees will explore solutions to persistent challenges in full/empty capsid quantification, aggregation profiling, and stability assay design, focusing on enhancing product quality and minimizing batch failures.

With expert insights from Spark Therapeutics, Novartis, Sarepta, Astellas, Beam, Regeneron, Eli Lilly, Bristol Myers Squibb, and more, this is the must-attend meeting for those advancing gene therapy analytics.

Key highlights include:

- How companies are aligning assay strategies with IND, BLA, and RMAT requirements to meet regulatory expectations and speed up development timelines

- The integration of tools like long-read sequencing, mass photometry, analytical ultracentrifugation, and digital PCR into GMP-ready, QC-compatible workflows

- Real-world strategies to overcome limitations of under-validated techniques that are slowing next-generation programs

URLs:

Tickets: https://go.evvnt.com/3115369-2?pid=10008

Brochure: https://go.evvnt.com/3115369-3?pid=10008

Time: 8:00 AM - 5:15 PM

Prices:

Conference + Workshop Day - Drug Developer Pricing: USD 4197.00,

Conference Only - Drug Developer Pricing: USD 2999.00,

Conference + Workshop Day - Academic Pricing: USD 3597.00,

Conference Only - Academic Pricing: USD 2599.00,

Conference + Workshop Day - Solution and Service Provider Pricing: USD 5097.00,

Conference Only - Drug Developer Pricing: USD 3699.00

Speakers: Anthony Blaszczyk, Senior Scientist, U.S. Pharmacopeia, Athea Vichas, Senior Principal Scientist, Bristol Myers Squibb, Brooke Brown, Principal Scientist, Novartis AG, Chynna Broxton, Analytical Development Scientist, Spark Therapeutics, Inc., Crystal Bryan, Associate Director - Quality Control and Analytical Technologies, Editas Medicine, Damon Barbacci, Director - Analytical Development, Genentech, Debojit Bose, Principal Scientist, Regeneron Pharmaceuticals, Haiqing Yu, Senior Scientist and Team Manager - Analytical Development and Quality Control, Sanofi, Jeanette Young, Director for cell and gene therapy method and Tech transfer, Astellas Pharma, Jimmy Zhong, Scientist, Tessera Therapeutics, Johnson Varghese, Vice President - Analytical Sciences and Development, Beam Therapeutics Inc., Kan Zhu, Director, CSL, Luis Rascon, Senior Associate - Research and Analytical Development, Astellas Pharma, Margaret Butko, Director - Assay Development, Chemistry, Manufacturing and Controls, Adverum, Marina Feschenko, Head of Analytical and Formulation Drug Product Sciences, Voyager Therapeutics, Inc, Prateek Tripathi, Senior Expert - Science and Technology, Novartis AG, Rishi Kothari, Process Development Engineer, Regeneron Pharmaceuticals, Sarah Tuller, CRO, Opus Genetics, Scott Jeffers, Chief Technology Officer, GenSight Biologics, Sue Duan, Head of Analytical Development, Astellas Pharma, Suman Jangid, Director - Global Regulatory Chemistry, Manufacturing, Controls and Gene Therapy, BridgeBio Pharma, Inc., Susan Tam, Quality Control Analyst, Astellas Pharma, Susumu Uchiyama, Professor, Osaka University, T.J. Craddick, Head of Genome Editing, CRISPR Therapeutics, Tyler Lindgren, Associate Scientist II, BridgeBio Pharma, Inc., Uditha DeAlwis, Vice President - Analytical Development and Quality Control, Sarepta Therapeutics, Vanessa Strings-Ufombah, Executive Director, CMC Assay and Drug Product Development, Adverum Biotechnologies, Wei Zhang, Director - Chemistry Manufacturing and Controls Leader, Ultragenyx Pharmaceutical Inc, Wesley Jackson, Senior Principal Biophysical Chemist, Eli Lilly and Co., Win Cheung, Senior Director - Analytical Development, REGENXBIO